biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

Inherited Metabolic Disorders: From Bench to Bedside

Guest Editors:

Dr. Fatima Macedo
1. Cell Activation and Gene Expression Group, Instituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
2. Department of Medical Sciences, University of Aveiro (UA), 3810-193 Aveiro, Portugal

Dr. Hugo Rocha
1. Newborn Screening, Metabolism and Genetics Unit, Human Genetics Department, National Institute of Health Doutor Ricardo Jorge, Porto, Portugal
2. Superior School of Health, Polytechnic Institute of Porto, Porto, Portugal

Deadline for manuscript submissions:
closed (28 February 2023)

Message from the Guest Editors

Dear Colleagues,

Inherited metabolic disorders are a growing group of genetic disorders that affect cellular metabolism, resulting in a wide range of clinical signs and symptoms. The dynamics of scientific breakthroughs in this field is unprecedented, from newborn screening to new therapies, and is positively changing patients' lives.

This Special Issue is devoted to publishing results on any features of inherited metabolic disorders, including newborn screening, diagnosis, basic research on molecular mechanisms, translational studies on novel therapies, and clinical investigations. Review articles on all these aspects are also welcome. The full spectrum of inherited metabolic disorders will be considered, including the lysosomal storage disorders.

This Special Issue will provide a comprehensive view of the diagnostic, molecular and clinical aspects of various inborn errors of metabolism. It comprehensively covers many areas in the field of inherited metabolic disorders, and could be of interest to a broad range of readers including physicians and other health-related professionals, scientists, students, and inherited metabolic disorders communities.

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI